Improving the bioavailability of peptide-based therapeutics for the treatment of Multiple Sclerosis

提高治疗多发性硬化症的肽疗法的生物利用度

• 批准号: nhmrc : 536578
• 负责人: Dr Conan Wang
• 金额: $ 22.75万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-bioavailability-peptide-multiple-sclerosis/115859
• 关键词: Improving; bioavailability; peptide; based; therapeutics

Many diseases are controlled at the molecular level by proteins and their interactions with other proteins. Harmonin is a key protein in Usher syndrome, the most common form of deaf-blindness in humans, and harmonin has similarities to some proteins involved in Alzheimer’s disease. We seek to understand how harmonin works. The findings of this study may lead to new treatments for deaf-blindness and Alzheimer’s disease.

许多疾病在分子水平上由蛋白质及其与其他蛋白质的相互作用控制。Harmonin是Usher综合征中的一种关键蛋白质，Usher综合征是人类最常见的眼盲症，Harmonin与阿尔茨海默病中的一些蛋白质有相似之处。我们试图了解和声是如何工作的。这项研究的发现可能会导致新的治疗失明和阿尔茨海默病。